Laumas Sandeep — SEC Form 4 filings
SEC reporting owner CIK 1721664. 10 Form 4 filings on record with FilingPulse; latest filed 2026-07-28.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-02-13 to 2026-07-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 1 filing — 30,000 shares, $701,667 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: sale of 17,539 shares @ $23.04 ($404,099) in Instil Bio, Inc., filed 2025-09-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Instil Bio, Inc. (TIL) | CFO and CBO | 4 | — | 2 legs · 30,000 sh · $701,667 | 7 |
| Unicycive Therapeutics, Inc. (UNCY) | Director | 4 | — | — | 6 |
| BioXcel Therapeutics, Inc. (BTAI) | Director | 2 | — | — | 2 |
Form 4 filings — Laumas Sandeep
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-28 | 4/A | Unicycive Therapeutics, Inc. (UNCY) | Grant/award (A): 47,941 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4/A | Unicycive Therapeutics, Inc. (UNCY) | Grant/award (A): 84,200 (derivative) @ $0 · Grant/award (A): 42,100 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Unicycive Therapeutics, Inc. (UNCY) | Grant/award (A): 84,200 (derivative) @ $0 · Grant/award (A): 42,100 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Instil Bio, Inc. (TIL) | Option exercise (M): 17,000 @ $11.60 · Option exercise (M): 13,000 @ $12.68 · Sale (S): 17,539 @ $23.04 · Sale (S): 12,461 @ $23.88 · Option exercise (M): 17,000 (derivative) @ $0 · Option exercise (M): 13,000 (derivative) @ $0 | EDGAR |
| 2025-07-30 | 4 | Unicycive Therapeutics, Inc. (UNCY) | Grant/award (A): 21,200 (derivative) @ $0 | EDGAR |
| 2025-04-28 | 4 | Instil Bio, Inc. (TIL) | Grant/award (A): 44,851 (derivative) @ $0 | EDGAR |
| 2024-09-23 | 4 | Instil Bio, Inc. (TIL) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-06-11 | 4 | BioXcel Therapeutics, Inc. (BTAI) | Grant/award (A): 17,000 (derivative) @ $0 | EDGAR |
| 2024-02-13 | 4 | Instil Bio, Inc. (TIL) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1721664 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →